{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:26:28Z","timestamp":1777566388656,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T00:00:00Z","timestamp":1504310400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-10-LABX-33"],"award-info":[{"award-number":["ANR-10-LABX-33"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-14-JAMR-0002"],"award-info":[{"award-number":["ANR-14-JAMR-0002"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003990","name":"Conseil R\u00e9gional, \u00cele-de-France","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003990","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s10822-017-0054-1","type":"journal-article","created":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T20:54:14Z","timestamp":1504299254000},"page":"273-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations"],"prefix":"10.1007","volume":"32","author":[{"given":"Edithe","family":"Selwa","sequence":"first","affiliation":[]},{"given":"Eddy","family":"Elis\u00e9e","sequence":"additional","affiliation":[]},{"given":"Agustin","family":"Zavala","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0392-1350","authenticated-orcid":false,"given":"Bogdan I.","family":"Iorga","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2017,9,2]]},"reference":[{"issue":"8","key":"54_CR1","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1358\/dnp.2004.17.8.863693","volume":"17","author":"D Bishop-Bailey","year":"2004","unstructured":"Bishop-Bailey D (2004) FXR as a novel therapeutic target for vascular disease. Drug News Perspect 17(8):499\u2013504","journal-title":"Drug News Perspect"},{"issue":"9","key":"54_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1517\/13543784.13.9.1135","volume":"13","author":"T Claudel","year":"2004","unstructured":"Claudel T, Sturm E, Kuipers F, Staels B (2004) The farnesoid X receptor: a novel drug target? Expert Opin Investig Drugs 13(9):1135\u20131148. doi:\n                    10.1517\/13543784.13.9.1135","journal-title":"Expert Opin Investig Drugs"},{"issue":"17","key":"54_CR3","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1021\/jm0582221","volume":"48","author":"R Pellicciari","year":"2005","unstructured":"Pellicciari R, Costantino G, Fiorucci S (2005) Farnesoid X receptor: from structure to potential clinical applications. J Med Chem 48(17):5383\u20135403. doi:\n                    10.1021\/jm0582221","journal-title":"J Med Chem"},{"issue":"8","key":"54_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2174\/1389557054553802","volume":"5","author":"S Westin","year":"2005","unstructured":"Westin S, Heyman RA, Martin R (2005) FXR, a therapeutic target for bile acid and lipid disorders. Mini Rev Med Chem 5(8):719\u2013727. doi:\n                    10.2174\/1389557054553802","journal-title":"Mini Rev Med Chem"},{"issue":"3","key":"54_CR5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1517\/14728222.10.3.409","volume":"10","author":"SY Cai","year":"2006","unstructured":"Cai SY, Boyer JL (2006) FXR: a target for cholestatic syndromes? Expert Opin Ther Targets 10(3):409\u2013421. doi:\n                    10.1517\/14728222.10.3.409","journal-title":"Expert Opin Ther Targets"},{"issue":"10","key":"54_CR6","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.tibs.2006.08.002","volume":"31","author":"FY Lee","year":"2006","unstructured":"Lee FY, Lee H, Hubbert ML, Edwards PA, Zhang Y (2006) FXR, a multipurpose nuclear receptor. Trends Biochem Sci 31(10):572\u2013580. doi:\n                    10.1016\/j.tibs.2006.08.002","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"54_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.tips.2007.03.002","volume":"28","author":"B Cariou","year":"2007","unstructured":"Cariou B, Staels B (2007) FXR: a promising target for the metabolic syndrome?. Trends Pharmacol Sci 28(5):236\u2013243. doi:\n                    10.1016\/j.tips.2007.03.002","journal-title":"Trends Pharmacol Sci"},{"issue":"5","key":"54_CR8","doi-asserted-by":"publisher","first-page":"621","DOI":"10.14670\/hh-23.621","volume":"23","author":"YD Wang","year":"2008","unstructured":"Wang YD, Chen WD, Huang W (2008) FXR, a target for different diseases. Histol Histopathol 23(5):621\u2013627. doi:\n                    10.14670\/hh-23.621","journal-title":"Histol Histopathol"},{"issue":"5","key":"54_CR9","doi-asserted-by":"publisher","first-page":"540","DOI":"10.2174\/187152008784533008","volume":"8","author":"A Zimber","year":"2008","unstructured":"Zimber A, Gespach C (2008) Bile acids and derivatives, their nuclear receptors FXR, PXR and ligands: role in health and disease and their therapeutic potential. Anticancer Agents Med Chem 8(5):540\u2013563. doi:\n                    10.2174\/187152008784533008","journal-title":"Anticancer Agents Med Chem"},{"issue":"8","key":"54_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1517\/13543776.2010.496777","volume":"20","author":"ML Crawley","year":"2010","unstructured":"Crawley ML (2010) Farnesoid X receptor modulators: a patent review. Expert Opin Ther Pat 20(8):1047\u20131057. doi:\n                    10.1517\/13543776.2010.496777","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"54_CR11","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2174\/092986710790112666","volume":"17","author":"S Fiorucci","year":"2010","unstructured":"Fiorucci S, Mencarelli A, Distrutti E, Palladino G, Cipriani S (2010) Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. Curr Med Chem 17(2):139\u2013159. doi:\n                    10.2174\/092986710790112666","journal-title":"Curr Med Chem"},{"issue":"1\u20132","key":"54_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1582-4934.2009.00997.x","volume":"14","author":"A Mencarelli","year":"2010","unstructured":"Mencarelli A, Fiorucci S (2010) FXR an emerging therapeutic target for the treatment of atherosclerosis. J Cell Mol Med 14(1\u20132):79\u201392. doi:\n                    10.1111\/j.1582-4934.2009.00997.x","journal-title":"J Cell Mol Med"},{"issue":"11","key":"54_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.tem.2011.07.002","volume":"22","author":"JS Teodoro","year":"2011","unstructured":"Teodoro JS, Rolo AP, Palmeira CM (2011) Hepatic FXR: key regulator of whole-body energy metabolism. Trends Endocrinol Metab 22(11):458\u2013466. doi:\n                    10.1016\/j.tem.2011.07.002","journal-title":"Trends Endocrinol Metab"},{"issue":"17\u201318","key":"54_CR14","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.drudis.2012.05.012","volume":"17","author":"L Adorini","year":"2012","unstructured":"Adorini L, Pruzanski M, Shapiro D (2012) Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Drug Discov Today 17(17\u201318):988\u2013997. doi:\n                    10.1016\/j.drudis.2012.05.012","journal-title":"Drug Discov Today"},{"issue":"7","key":"54_CR15","doi-asserted-by":"publisher","first-page":"877","DOI":"10.4155\/fmc.12.41","volume":"4","author":"S Fiorucci","year":"2012","unstructured":"Fiorucci S, Mencarelli A, Distrutti E, Zampella A (2012) Farnesoid X receptor: from medicinal chemistry to clinical applications. Future Med Chem 4(7):877\u2013891. doi:\n                    10.4155\/fmc.12.41","journal-title":"Future Med Chem"},{"issue":"6","key":"54_CR16","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2174\/156802612799436678","volume":"12","author":"S Fiorucci","year":"2012","unstructured":"Fiorucci S, Zampella A, Distrutti E (2012) Development of FXR, PXR and CAR agonists and antagonists for treatment of liver disorders. Curr Top Med Chem 12(6):605\u2013624. doi:\n                    10.2174\/156802612799436678","journal-title":"Curr Top Med Chem"},{"issue":"7","key":"54_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1093\/bioinformatics\/btt055","volume":"29","author":"S Pronk","year":"2013","unstructured":"Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts MR, Smith JC, Kasson PM, van der Spoel D, Hess B, Lindahl E (2013) GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics 29(7):845\u2013854. doi:\n                    10.1093\/bioinformatics\/btt055","journal-title":"Bioinformatics"},{"issue":"19","key":"54_CR18","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.2174\/1568026614666141112094058","volume":"14","author":"A Carotti","year":"2014","unstructured":"Carotti A, Marinozzi M, Custodi C, Cerra B, Pellicciari R, Gioiello A, Macchiarulo A (2014) Beyond bile acids: targeting Farnesoid X Receptor (FXR) with natural and synthetic ligands. Curr Top Med Chem 14(19):2129\u20132142. doi:\n                    10.2174\/1568026614666141112094058","journal-title":"Curr Top Med Chem"},{"issue":"12","key":"54_CR19","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1517\/14728222.2014.956087","volume":"18","author":"S Fiorucci","year":"2014","unstructured":"Fiorucci S, Distrutti E, Ricci P, Giuliano V, Donini A, Baldelli F (2014) Targeting FXR in cholestasis: hype or hope. Expert Opin Ther Targets 18(12):1449\u20131459. doi:\n                    10.1517\/14728222.2014.956087","journal-title":"Expert Opin Ther Targets"},{"issue":"19","key":"54_CR20","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.2174\/1568026614666141112094430","volume":"14","author":"C Gege","year":"2014","unstructured":"Gege C, Kinzel O, Steeneck C, Schulz A, Kremoser C (2014) Knocking on FXR\u2019s door: the \u201chammerhead\"-structure series of FXR agonists: amphiphilic isoxazoles with potent in vitro and in vivo activities. Curr Top Med Chem 14(19):2143\u20132158. doi:\n                    10.2174\/1568026614666141112094430","journal-title":"Curr Top Med Chem"},{"issue":"19","key":"54_CR21","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.2174\/1568026614666141112101840","volume":"14","author":"H Huang","year":"2014","unstructured":"Huang H, Xu Y, Zhu J, Li J (2014) Recent advances in non-steroidal FXR antagonists development for therapeutic applications. Curr Top Med Chem 14(19):2175\u20132187. doi:\n                    10.2174\/1568026614666141112101840","journal-title":"Curr Top Med Chem"},{"issue":"19","key":"54_CR22","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2174\/1568026614666141112103516","volume":"14","author":"C Lamers","year":"2014","unstructured":"Lamers C, Schubert-Zsilavecz M, Merk D (2014) Medicinal chemistry and pharmacological effects of Farnesoid X Receptor (FXR) antagonists. Curr Top Med Chem 14(19):2188\u20132205. doi:\n                    10.2174\/1568026614666141112103516","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"54_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3978\/j.issn.2305-5839.2014.12.06","volume":"3","author":"AH Ali","year":"2015","unstructured":"Ali AH, Carey EJ, Lindor KD (2015) Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med 3(1):5. doi:\n                    10.3978\/j.issn.2305-5839.2014.12.06","journal-title":"Ann Transl Med"},{"issue":"4","key":"54_CR24","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s11883-015-0500-2","volume":"17","author":"RM Carr","year":"2015","unstructured":"Carr RM, Reid AE (2015) FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep 17(4):500. doi:\n                    10.1007\/s11883-015-0500-2","journal-title":"Curr Atheroscler Rep"},{"issue":"4","key":"54_CR25","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1517\/17425255.2014.999664","volume":"11","author":"I Koutsounas","year":"2015","unstructured":"Koutsounas I, Theocharis S, Delladetsima I, Patsouris E, Giaginis C (2015) Farnesoid X receptor in human metabolism and disease: the interplay between gene polymorphisms, clinical phenotypes and disease susceptibility. Expert Opin Drug Metab Toxicol 11(4):523\u2013532. doi:\n                    10.1517\/17425255.2014.999664","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"54_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1159\/000371698","volume":"33","author":"AJ Sanyal","year":"2015","unstructured":"Sanyal AJ (2015) Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease. Dig Dis 33(3):426\u2013432. doi:\n                    10.1159\/000371698","journal-title":"Dig Dis"},{"issue":"8","key":"54_CR27","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1517\/13543776.2015.1045413","volume":"25","author":"V Sepe","year":"2015","unstructured":"Sepe V, Distrutti E, Fiorucci S, Zampella A (2015) Farnesoid X receptor modulators (2011\u20132014): a patent review. Expert Opin Ther Pat 25(8):885\u2013896. doi:\n                    10.1517\/13543776.2015.1045413","journal-title":"Expert Opin Ther Pat"},{"issue":"9","key":"54_CR28","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.4155\/fmc.15.54","volume":"7","author":"V Sepe","year":"2015","unstructured":"Sepe V, Distrutti E, Limongelli V, Fiorucci S, Zampella A (2015) Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application. Future Med Chem 7(9):1109\u20131135. doi:\n                    10.4155\/fmc.15.54","journal-title":"Future Med Chem"},{"issue":"12","key":"54_CR29","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1007\/s10620-016-4334-8","volume":"61","author":"AS Alawad","year":"2016","unstructured":"Alawad AS, Levy C (2016) FXR agonists: from bench to bedside, a guide for clinicians. Dig Dis Sci 61(12):3395\u20133404. doi:\n                    10.1007\/s10620-016-4334-8","journal-title":"Dig Dis Sci"},{"issue":"3","key":"54_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1159\/000450909","volume":"35","author":"CD Magalhaes Filho De","year":"2017","unstructured":"De Magalhaes Filho CD, Downes M, Evans RM (2017) Farnesoid X Receptor an emerging target to combat obesity. Dig Dis 35(3):185\u2013190. doi:\n                    10.1159\/000450909","journal-title":"Dig Dis"},{"issue":"9","key":"54_CR31","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1016\/j.bmcl.2009.03.008","volume":"19","author":"S Feng","year":"2009","unstructured":"Feng S, Yang M, Zhang Z, Wang Z, Hong D, Richter H, Benson GM, Bleicher K, Grether U, Martin RE, Plancher JM, Kuhn B, Rudolph MG, Chen L (2009) Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist. Bioorg Med Chem Lett 19(9):2595\u20132598. doi:\n                    10.1016\/j.bmcl.2009.03.008","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"54_CR32","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.bmcl.2010.12.123","volume":"21","author":"HG Richter","year":"2011","unstructured":"Richter HG, Benson GM, Bleicher KH, Blum D, Chaput E, Clemann N, Feng S, Gardes C, Grether U, Hartman P, Kuhn B, Martin RE, Plancher JM, Rudolph MG, Schuler F, Taylor S (2011) Optimization of a novel class of benzimidazole-based farnesoid X receptor (FXR) agonists to improve physicochemical and ADME properties. Bioorg Med Chem Lett 21(4):1134\u20131140. doi:\n                    10.1016\/j.bmcl.2010.12.123","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"54_CR33","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.bmcl.2010.11.039","volume":"21","author":"HG Richter","year":"2011","unstructured":"Richter HG, Benson GM, Blum D, Chaput E, Feng S, Gardes C, Grether U, Hartman P, Kuhn B, Martin RE, Plancher JM, Rudolph MG, Schuler F, Taylor S, Bleicher KH (2011) Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes. Bioorg Med Chem Lett 21(1):191\u2013194. doi:\n                    10.1016\/j.bmcl.2010.11.039","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"54_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/nar\/28.1.235","volume":"28","author":"HM Berman","year":"2000","unstructured":"Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE (2000) The Protein Data Bank. Nucleic Acids Res 28(1):235\u2013242. doi:\n                    10.1093\/nar\/28.1.235","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"54_CR35","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","volume":"234","author":"A Sali","year":"1993","unstructured":"Sali A, Blundell TL (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol 234(3):779\u2013815. doi:\n                    10.1006\/jmbi.1993.1626","journal-title":"J Mol Biol"},{"issue":"4","key":"54_CR36","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/prot.10465","volume":"52","author":"ML Verdonk","year":"2003","unstructured":"Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD (2003) Improved protein\u2013ligand docking using GOLD. Proteins Struct Funct Bioinf 52(4):609\u2013623. doi:\n                    10.1002\/prot.10465","journal-title":"Proteins Struct Funct Bioinf"},{"issue":"16","key":"54_CR37","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30(16):2785\u20132791. doi:\n                    10.1002\/jcc.21256","journal-title":"J Comput Chem"},{"issue":"13","key":"54_CR38","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/jcc.20084","volume":"25","author":"EF Pettersen","year":"2004","unstructured":"Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE (2004) UCSF Chimera: a visualization system for exploratory research and analysis. J Comput Chem 25(13):1605\u20131612. doi:\n                    10.1002\/jcc.20084","journal-title":"J Comput Chem"},{"issue":"2","key":"54_CR39","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31(2):455\u2013461. doi:\n                    10.1002\/jcc.21334","journal-title":"J Comput Chem"},{"issue":"28","key":"54_CR40","doi-asserted-by":"publisher","first-page":"6474","DOI":"10.1021\/jp003919d","volume":"105","author":"GA Kaminski","year":"2001","unstructured":"Kaminski GA, Friesner RA, Tirado-Rives J, Jorgensen WL (2001) Evaluation and reparametrization of the OPLS-AA force field for proteins via comparison with accurate quantum chemical calculations on peptides. J Phys Chem B 105(28):6474\u20136487. doi:\n                    10.1021\/jp003919d","journal-title":"J Phys Chem B"},{"issue":"7","key":"54_CR41","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1021\/acs.jctc.5b00356","volume":"11","author":"MJ Robertson","year":"2015","unstructured":"Robertson MJ, Tirado-Rives J, Jorgensen WL (2015) Improved peptide and protein torsional energetics with the OPLS-AA force field. J Chem Theory Comput 11(7):3499\u20133509. doi:\n                    10.1021\/acs.jctc.5b00356","journal-title":"J Chem Theory Comput"},{"issue":"5","key":"54_CR42","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/jcc.23804","volume":"36","author":"V Gapsys","year":"2015","unstructured":"Gapsys V, Michielssens S, Seeliger D, de Groot BL (2015) pmx: Automated protein structure and topology generation for alchemical perturbations. J Comput Chem 36(5):348\u2013354. doi:\n                    10.1002\/jcc.23804","journal-title":"J Comput Chem"},{"key":"54_CR43","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-1-4939-1465-4_9","volume":"1215","author":"V Gapsys","year":"2015","unstructured":"Gapsys V, Michielssens S, Peters JH, de Groot BL, Leonov H (2015) Calculation of binding free energies. Methods Mol Biol 1215:173\u2013209. doi:\n                    10.1007\/978-1-4939-1465-4_9","journal-title":"Methods Mol Biol"},{"issue":"26","key":"54_CR44","doi-asserted-by":"publisher","first-page":"7364","DOI":"10.1002\/anie.201510054","volume":"55","author":"V Gapsys","year":"2016","unstructured":"Gapsys V, Michielssens S, Seeliger D, de Groot BL (2016) Accurate and rigorous prediction of the changes in protein free energies in a large-scale mutation scan. Angew Chem 55(26):7364\u20137368. doi:\n                    10.1002\/anie.201510054","journal-title":"Angew Chem"},{"issue":"5","key":"54_CR45","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10822-011-9526-x","volume":"26","author":"G Surpateanu","year":"2012","unstructured":"Surpateanu G, Iorga BI (2012) Evaluation of docking performance in a blinded virtual screening of fragment-like trypsin inhibitors. J Comput Aided Mol Des 26(5):595\u2013601. doi:\n                    10.1007\/s10822-011-9526-x","journal-title":"J Comput Aided Mol Des"},{"issue":"4","key":"54_CR46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10822-014-9707-5","volume":"28","author":"C Colas","year":"2014","unstructured":"Colas C, Iorga BI (2014) Virtual screening of the SAMPL4 blinded HIV integrase inhibitors dataset. J Comput Aided Mol Des 28(4):455\u2013462. doi:\n                    10.1007\/s10822-014-9707-5","journal-title":"J Comput Aided Mol Des"},{"issue":"6","key":"54_CR47","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1021\/acs.jcim.5b00337","volume":"56","author":"VY Martiny","year":"2016","unstructured":"Martiny VY, Martz F, Selwa E, Iorga BI (2016) Blind pose prediction, scoring, and affinity ranking of the CSAR 2014 dataset. J Chem Inf Model 56(6):996\u20131003. doi:\n                    10.1021\/acs.jcim.5b00337","journal-title":"J Chem Inf Model"},{"issue":"9","key":"54_CR48","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1007\/s10822-016-9983-3","volume":"30","author":"E Selwa","year":"2016","unstructured":"Selwa E, Martiny VY, Iorga BI (2016) Molecular docking performance evaluated on the D3R Grand Challenge 2015 drug-like ligand datasets. J Comput Aided Mol Des 30(9):829\u2013839. doi:\n                    10.1007\/s10822-016-9983-3","journal-title":"J Comput Aided Mol Des"},{"key":"54_CR49","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3762\/bjoc.12.45","volume":"12","author":"J Grunenberg","year":"2016","unstructured":"Grunenberg J, Licari G (2016) Effective in silico prediction of new oxazolidinone antibiotics: force field simulations of the antibiotic-ribosome complex supervised by experiment and electronic structure methods. Beilstein J Org Chem 12:415\u2013428. doi:\n                    10.3762\/bjoc.12.45","journal-title":"Beilstein J Org Chem"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10822-017-0054-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-017-0054-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-017-0054-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T15:42:54Z","timestamp":1552664574000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10822-017-0054-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,2]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["54"],"URL":"https:\/\/doi.org\/10.1007\/s10822-017-0054-1","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,2]]},"assertion":[{"value":"2 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}